Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application for levonorgestrel tablets, 0.75 mg, for women seventeen years and younger. Levonorgestrel is the generic equivalent to Duramed Pharmaceuticals' PLAN B(R), which is indicated for the prevention of pregnancy following unprotected intercourse or contraceptive failure. This product is approved for prescription use only. [more...]
|
|
|
